Proficio Capital Partners’s Y-mAbs Therapeutics YMAB Stock Holding History

Proficio Capital Partners’s Portfolio YMAB Stock Details YMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-17	Closed	–	–	2105
2019 Q1	$0	Buy	+17	New	+$373	﹤0.01%	1783

Other funds holding YMAB

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Proficio Capital Partners's YMAB Position: Q2 2019 in Review

Proficio Capital Partners sold out of Y-mAbs Therapeutics (YMAB) in Q2 2019, closing a stake of 17 shares.

Proficio Capital Partners first reported a position in YMAB in Q1 2019 and held it in 1 quarter. The position peaked at $0 in Q1 2019. 59 funds tracked by Wall St. Rank hold YMAB as of Q2 2019.

Proficio Capital Partners reported no remaining Y-mAbs Therapeutics position as of Q2 2019 after selling out during the quarter.
Proficio Capital Partners sold 17 Y-mAbs Therapeutics shares in Q2 2019.
Proficio Capital Partners first reported a position in Y-mAbs Therapeutics in Q1 2019 and held it in 1 quarter.
Proficio Capital Partners's Y-mAbs Therapeutics position peaked at $0 in Q1 2019.
59 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q2 2019.

Based on Proficio Capital Partners's 13F filing for Q2 2019, filed 13 Aug 2019.